AMES, Iowa--(BUSINESS WIRE)--
NewLink Genetics Corporation ("NewLink Genetics") (Nasdaq:NLNK), a
late-stage biopharmaceutical company, today announced that it intends to
offer and sell, subject to market conditions, up to $50,000,000 of
shares of its common stock in an underwritten public offering. All of
the shares of common stock to be sold in the offering will be offered by
NewLink Genetics. NewLink Genetics also intends to grant the
underwriters a 30-day option to purchase up to an additional $7,500,000
of shares of its common stock sold in the public offering on the same
terms and conditions. The offering is subject to market conditions, and
there can be no assurance as to whether or when the offering may be
completed, or the actual size or terms of the offering.
NewLink Genetics intends to use the net proceeds from the offering to
fund its research and development efforts to further advance its
pipeline of product candidates, including the continued clinical
development of indoximod, and for working capital and other general
corporate purposes.
BofA Merrill Lynch and Stifel will act as joint book-running managers
for the offering. Baird will act as co-manager for the offering.
A shelf registration statement relating to the shares of common stock
offered in the public offering described above was filed with
the Securities and Exchange Commission (SEC) on June 25, 2015 and
declared effective by the SEC on July 28, 2015. The offering will be
made only by means of a written prospectus and prospectus supplement
that form a part of the registration statement. A preliminary prospectus
supplement and accompanying prospectus relating to the offering will be
filed with the SEC and will be available on the SEC's website at www.sec.gov.
Copies of the preliminary prospectus supplement and the accompanying
prospectus, when available, may also be obtained by contacting BofA
Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor,
Charlotte NC 28255-0001, Attn: Prospectus Department, Email: dg.prospectus_requests@baml.com;
or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate,
One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by
telephone at (415) 364-2720, or by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor shall
there be any sale of the securities being offered in any state or other
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on
discovering, developing and commercializing novel immuno-oncology
product candidates to improve the lives of patients with cancer. NewLink
Genetics' IDO pathway inhibitors are designed to harness multiple
components of the immune system to combat cancer. Indoximod is being
evaluated in combination with treatment regimens including
anti-PD-1/PD-L1 agents, cancer vaccines, and chemotherapy across
multiple indications such as melanoma, prostate cancer, acute myeloid
leukemia, and pancreatic cancer.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of NewLink
Genetics that involve substantial risks and uncertainties. Any
statements in this press release about future expectations, plans and
prospects for NewLink Genetics, including statements about NewLink
Genetics's anticipated public offering and anticipated use of proceeds
are forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. The words "anticipate,"
"believe," "estimate," "expect," "intend," "may," "plan," "target,"
"potential," "will," "could," "should," "seek" or the negative of these
terms or other similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Actual results may differ materially
from those indicated by such forward-looking statements as a result of
various important factors, including: the uncertainties related to
market conditions and the completion of the public offering on the
anticipated terms or at all as well uncertainties inherent in the
initiation of future clinical trials. For a further description
of the risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well as
risks relating to NewLink Genetics's business in general, please refer
to NewLink Genetic's preliminary prospectus supplement to be filed with
the SEC on October 3, 2017, including the documents incorporated by
reference therein. The forward-looking statements in this press release
represent NewLink Genetics' views as of the date of this press
release. NewLink Genetics anticipates that subsequent events and
developments will cause its views to change. However, while NewLink
Genetics may elect to update these forward-looking statements at some
point in the future, it specifically disclaims any obligation to do
so. You should, therefore, not rely on these forward-looking statements
as representing NewLink Genetics' views as of any date subsequent to the
date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171003006505/en/
Investors:
NewLink Genetics
Lisa Miller, 515-598-2555
Director
of Investor Relations
lmiller@linkp.com
or
Media:
LaVoieHealthScience
Andrew
Mastrangelo, 617-374-8800, ext. 108
AVP, Public & Media Relations
amastrangelo@lavoiehealthscience.com
Source: NewLink Genetics Corporation
News Provided by Acquire Media